Aptadir Therapeutics has secured a β¬40M seed round led by UK-based 4BIO Capital, one of the largest seed financings in European biotech this year. The deal was reported October 6, 2026, in BeBeez's weekly Italy venture capital roundup, and underscores how much capital is flowing into early-stage life sciences on the continent.
Who's Behind the Aptadir Therapeutics Seed
Founded in 2023 by Annalisa Di Ruscio, Daniel Tenen, Vittorio de Franciscis, Giovanni Amabile, and Marcin Kortylewski, Aptadir brings together academic and industry expertise in RNA-targeted therapeutics β one of the most active frontiers in drug development.
The syndicate behind the round is broad and notably Italian-anchored: alongside 4BIO Capital participated EXTEND (the joint initiative of CDP Venture Capital, Angelini Ventures, and Evotec), CDP Venture Capital β Digital Transition, Indaco Venture Partners, Xgen Ventures, the Bio Lombardia FundβCE Ventures (backed by the European Fund for Regional Development), Kerna Ventures, Italian Angels for Biotech, and Club degli Investitori β Simon Fiduciaria.
That mix β a specialist UK lead, Italian institutional capital, European regional development funds, and angel networks β is the modern European biotech funding stack in miniature. A β¬40M seed doesn't get raised on hope alone; it reflects a platform technology with a credible path through preclinical development and into the clinic.
Why a β¬40M Seed Makes Sense in Biotech
In software, a β¬40M seed would raise eyebrows. In biotech, it's increasingly standard for platform companies. Drug development is capital-intensive from day one: lab infrastructure, specialized talent, and years of preclinical work precede any clinical readout. Investors who understand the category size their seed rounds to give the company a real shot at generating the data that justifies a Series A β typically two to three years of runway.
The participation of Evotec β via the EXTEND initiative β is a particularly interesting signal. Evotec is a major drug-discovery partner to the pharma industry; its involvement suggests industrial validation of the underlying science, not just venture appetite.
Italy's Biotech Moment
The round is also a data point in Italy's growing life-sciences momentum. With CDP Venture Capital, Angelini Ventures, Indaco, and regional funds all in the syndicate, Aptadir is drawing on a maturing domestic ecosystem that increasingly keeps world-class science funded at home rather than watching it migrate to Boston or Basel. For European investors, the message is that Italy's biotech pipeline is producing companies capable of attracting tier-one specialist leads like 4BIO.
Why It Matters for Founders and Investors
For biotech founders, Aptadir's round is a template: assemble a founding team with deep scientific credibility, anchor the syndicate with a specialist lead, and layer in strategic and regional capital that de-risks the story for everyone. The Evotec angle shows that industrial partnerships can substitute for traction in preclinical companies.
For investors, the β¬40M figure is a reminder that European biotech seed rounds have scaled to match the science. RNA-targeted therapeutics remains one of the hottest areas in drug development, and the breadth of this syndicate β from angels to regional development funds β shows that capital is available across the stack for credible platforms. Expect continued strong seed-stage funding for platform biotech through 2027, particularly in modalities with clear pharma partnering potential.
Angeled.com connects founders with investors.
Read Next
General Translation Raises $27 Million Series A Led by a16z to Build Agent-First Localization Infrastructure
LangChain Raises $300 Million Led by CapitalG at a $3 Billion Valuation to Build the Agent Stack
Mount Thor Raises $45 Million to Run Cloud Fleets of Macs for AI Agents
OpenAI Reportedly Raises $15 Billion at a $1.25 Trillion Valuation
Q-CTRL Raises $290 Million Series C Led by Salesforce Ventures, Reaching Unicorn Status
SE3 Raises $30 Million Series A Led by Accel



